Story thread · 3 reports / 3 sources
NeuroScientific locks in key US FDA meeting
smh.com.au · 1h · first report
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.